Bioharvest Sciences (BHST) Common Equity (2023 - 2025)

Bioharvest Sciences has reported Common Equity over the past 3 years, most recently at $25.4 million for Q4 2025.

  • Quarterly results put Common Equity at $25.4 million for Q4 2025, up 1813.38% from a year ago — trailing twelve months through Dec 2025 was $25.4 million (up 1813.38% YoY), and the annual figure for FY2025 was $25.4 million, up 1813.38%.
  • Common Equity for Q4 2025 was $25.4 million at Bioharvest Sciences, up from $1.3 million in the prior quarter.
  • Over the last five years, Common Equity for BHST hit a ceiling of $25.4 million in Q4 2025 and a floor of -$83.5 million in Q4 2023.
  • Median Common Equity over the past 3 years was $1.3 million (2024), compared with a mean of -$18.9 million.
  • Biggest five-year swings in Common Equity: surged 101.59% in 2024 and later soared 1813.38% in 2025.
  • Bioharvest Sciences' Common Equity stood at -$83.5 million in 2023, then surged by 101.59% to $1.3 million in 2024, then soared by 1813.38% to $25.4 million in 2025.
  • The last three reported values for Common Equity were $25.4 million (Q4 2025), $1.3 million (Q4 2024), and -$83.5 million (Q4 2023) per Business Quant data.